PAK4 and triple-negative breast carcinoma: Thus, our results indicate that orally administered KPT-9274 reduces the steady state level of PAK4 protein and is capable of reducing growth of the triple negative breast cancer cells MDA-MB-231, MDA-MB-468 and SUM159.